190 related articles for article (PubMed ID: 20019610)
1. Managing the toxicities of the aromatase inhibitors.
Mortimer JE
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):56-60. PubMed ID: 20019610
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Dent SF; Gaspo R; Kissner M; Pritchard KI
Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
[TBL] [Abstract][Full Text] [Related]
4. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
Cella D; Fallowfield LJ
Breast Cancer Res Treat; 2008 Jan; 107(2):167-80. PubMed ID: 17876703
[TBL] [Abstract][Full Text] [Related]
5. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
6. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
7. Menopausal symptoms and adjuvant therapy-associated adverse events.
Hadji P
Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
[TBL] [Abstract][Full Text] [Related]
8. Effectively nursing patients receiving aromatase inhibitor therapy.
Wengström Y
Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of aromatase inhibitors.
Pandya N; Morris GJ
Semin Oncol; 2006 Dec; 33(6):688-95. PubMed ID: 17145349
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
Coleman RE; Bolten WW; Lansdown M; Dale S; Jackisch C; Merkel D; Maass N; Hadji P
Cancer Treat Rev; 2008 May; 34(3):275-82. PubMed ID: 18082328
[TBL] [Abstract][Full Text] [Related]
12. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Bedard PL; Piccart-Gebhart MJ
Curr Opin Oncol; 2009 Nov; 21(6):491-8. PubMed ID: 19593135
[TBL] [Abstract][Full Text] [Related]
13. Tolerance of adjuvant letrozole outside of clinical trials.
Fontaine C; Meulemans A; Huizing M; Collen C; Kaufman L; De Mey J; Bourgain C; Verfaillie G; Lamote J; Sacre R; Schallier D; Neyns B; Vermorken J; De Grève J
Breast; 2008 Aug; 17(4):376-81. PubMed ID: 18455395
[TBL] [Abstract][Full Text] [Related]
14. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Abdulhaq H; Geyer C
Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Kyvernitakis I; Ziller V; Hars O; Bauer M; Kalder M; Hadji P
Climacteric; 2014 Jun; 17(3):252-9. PubMed ID: 23805799
[TBL] [Abstract][Full Text] [Related]
16. Managing patients on endocrine therapy: focus on quality-of-life issues.
Whelan TJ; Pritchard KI
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1056s-1060s. PubMed ID: 16467124
[TBL] [Abstract][Full Text] [Related]
17. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
20. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
Pfeiler G; Glatz C; Königsberg R; Geisendorfer T; Fink-Retter A; Kubista E; Singer CF; Seifert M
Climacteric; 2011 Jun; 14(3):339-44. PubMed ID: 21226657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
